CLAIM #56519 · Thermo Fisher Scientific Inc (TMO) · 2025Q1 earnings call · Apr 23, 2025 · due Dec 31, 2025
“We continue to estimate that full-year average diluted share count will be between 378 million and 379 million shares, and return approximately $600 million of capital to shareholders this year through dividends.”
Stephen Williamson · CFO
How to check this claim
Look at: Full-year average diluted share count and total dividends paid to shareholders, fiscal year 2025
It came true if: Average diluted share count between 378 million and 379 million shares AND dividends paid approximately $600 million (590-610 million)
Where: Company 10-K / Q4 2025 earnings release (income statement and cash flow statement - financing activities)
In context
“FX to be a year-over-year headwind to revenue of $50 million and a $90 million headwind to adjusted operating income. This includes an estimated $60 million of one-time transactional FX. In terms of adjusted EPS, we now expect FX to be a headwind of $0.19 for the year. Below the line, we now expect approximately $330 million of net interest expense in 2025. The adjusted tax rate assumption for the year is expected to be 10.5% versus our prior guide of 11.5%, reflecting the changes to our earnings guidance. We continue to expect between $1.4 billion and $1.7 billion of net capital expenditures in 2025 and free cash flow in a range of $7 billion to $7.4 billion for the year. In terms of capital deployment, we're assuming $2 billion of share buybacks, which were already completed in January. We continue to estimate that full-year average diluted share count will be between 378 million and 379 million shares, and return approximately $600 million of capital to shareholders this year through dividends. And our guidance does not include any future acquisitions or divestitures, so it does not include any impact from the pending acquisition of Soventum's purification and filtration business. Finally, I wanted to touch on phasing for Q2. We expect organic growth in Q2 to be similar to Q1, and adjusted EPS in Q2 to be approximately $0.05 to $0.10 higher than in Q1. So to conclude, in a more uncertain world, we delivered on our commitments in Q1. And while the world is more uncertain, what is unchanged is our approach. We're acting with agility, navigating appropriately, enabling the success of our customers, our colleagues, and our shareholders. With that, I'll turn the call back over to Raf. Rafael Tejada: Thank you, Steven. Operator, we're ready for the Q&A portion of the call. Operator: T”
Verify independently
SEC filings for TMO ↗ · Claim quote is verbatim from the 2025Q1 earnings call.